Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DPDMAX: DPD Activity and Capecitabine Efficacy in Metastatic Breast Cancer
NCT04198727Phase 2Active, not recruiting
- Sponsor
- Centre Antoine Lacassagne
- Start
- Jul 2020
- Primary completion
- Sep 2026
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of capecitabine in breast cancer, sponsored by Centre Antoine Lacassagne. Primary endpoint: Objective Response Rate at 6 months. Started Jul 2020; status: active, not recruiting.
02
Drugs
capecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04198727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04198727.